Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.77 |
| ▸ | BCHE | P06276 | 3/20 | 0.77 |
| ▸ | ACHE | P22303 | 3/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.74 |
| ▸ | LMNA | P02545 | 4/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.74 |
| ▸ | HTT | P42858 | 3/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | STAT3 | P40763 | 1/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.70 |
| ▸ | MAPT | P10636 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.70 |
| ▸ | POLB | P06746 | 2/20 | 0.70 |
| ▸ | HPGD | P15428 | 1/20 | 0.70 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11275576 | 0.87 | KMT2A (0.67) | EPHX2BCHEACHESMN1; SMN2LMNA | |
| SCHEMBL28020357 | 0.87 | BCHE (0.68) | EPHX2BCHEACHESMN1; SMN2LMNA | |
| SCHEMBL19427446 | 0.87 | EPHX2 (0.80) | EPHX2BCHEACHESMN1; SMN2LMNA | |
| SCHEMBL5313746 | 0.86 | GAA (0.81) | EPHX2BCHEACHESMN1; SMN2LMNA | |
| SCHEMBL7872336 | 0.85 | KMT2A (0.80) | EPHX2BCHEACHESMN1; SMN2LMNA | |
| SCHEMBL1645810 | 0.84 | KMT2A (0.71) | EPHX2BCHEACHESMN1; SMN2LMNA | |
| SCHEMBL2840181 | 0.83 | BCHE (0.63) | EPHX2BCHEACHESMN1; SMN2LMNA | |
| SCHEMBL28618230 | 0.82 | CHEK1 (0.63) | EPHX2BCHEACHESMN1; SMN2LMNA | |
| SCHEMBL4047959 | 0.82 | EPHX2 (0.67) | EPHX2BCHEACHESMN1; SMN2LMNA | |
| SCHEMBL7243154 | 0.82 | LMNA (0.69) | EPHX2BCHEACHESMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394835-B2 | Aromatic compounds and their use in medical applications | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2013-03-12 | — | — | US | disclosed |
| US-8367677-B2 | Comprising trihydroxy phenyl subunits; selectin inhibitors; side effect reduction; 3-{3-[3-(3,4,5-Trihydroxy-phenyl)-propionylamino]-phenylamino}-benzoic acid | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2013-02-05 | — | — | US | disclosed |
| US-20110152291-A1 | NOVEL AROMATIC COMPOUNDS AND THEIR USE IN MEDICAL APPLICATIONS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2011-06-23 | — | — | US | disclosed |
| US-7923473-B2 | Moderate binding of selectins ; chronic obstructive pulmonary disease; Crohn's disease; sepsis; antiinflammatory agents; skin disorders; antiarthritic agents; cardiovascular disorders; autoimmune diseases ' | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2011-04-12 | — | — | US | disclosed |
| EP-2195029-A2 | TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES | Oryzon Genomics SA (ES) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009027349-A2 | TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES | ORYZON GENOMICS SA (ES) | 2009-03-05 | — | — | WO | disclosed |
| US-20080249107-A1 | Non-Glycosylated/Non-Glycosidic/Non-Peptidic Small Molecule Psgl-1 Mimetics for the Treatment of Inflammatory Disorders | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2008-10-09 | — | — | US | disclosed |
| US-20080207639-A1 | Novel Aromatic Compounds and Their Use in Medical Applications | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152291-A1 | NOVEL AROMATIC COMPOUNDS AND THEIR USE IN MEDICAL APPLICATIONS | SELP, SELL, SELE | EPHX2 1280/4885BCHE 4075/4885ACHE 3558/4885 |
| US-20080207639-A1 | Novel Aromatic Compounds and Their Use in Medical Applications | SELP, SELL, SELE | EPHX2 1133/4885BCHE 4100/4885ACHE 3513/4885 |
| US-20080249107-A1 | Non-Glycosylated/Non-Glycosidic/Non-Peptidic Small Molecule Psgl-1 Mimetics for the Treatment of Inflammatory Disorders | SELP, SELPLG, SELE | EPHX2 2645/4885BCHE 2604/4885ACHE 4695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.